Abstract

Seven hexacoordinated cis-dioxidomolybdenum(VI) complexes [MoO2L1–7] (1‐7) derived from various tetradentate diamino bis(phenolato) “salan” ligands, N,N′-dimethyl-N,N′-bis-(2-hydroxy-3-X-5-Y-6-Z-benzyl)-1,2-diaminoethane {(X=Br, Y=Me, Z=H (H2L1); X=Me, YCl, Z=H (H2L2); X=iPr, Y=Cl, Z=Me (H2L3)} and N,N′-bis-(2-hydroxy-3-X–5-Y-6-Z-benzyl)-1,2-diaminopropane {(X=Y=tBu, Z=H (H2L4); X=Y=Me, Z=H (H2L5); X=iPr, YCl, Z=Me (H2L6); X=Y=Br, Z=H (H2L7)} containing O‐N donor atoms, have been isolated and structurally characterized. The formation of cis-dioxidomolybdenum(VI) complexes was confirmed by elemental analysis, IR, UV–vis and NMR spectroscopy, ESI-MS and cyclic voltammetry. X-ray crystallography showed the O2N2 donor set to define an octahedral geometry in each case. The complexes (1–7) were tested for their in vitro antiproliferative activity against HT-29 and HeLa cancer cell line. IC50 values of the complexes in HT-29 follow the order 6<7<<1<2<5<<3<4 while the order was 6<7<5<1<<3<4<2 in HeLa cells. Some of the complexes proved to be as active as the clinical referred drugs, and the greater potency of 6 and 7 (IC50 values of 6 are 2.62 and 10.74μM and that of 7 is 11.79 and 30.48μM in HT-29 and HeLa cells, respectively) may be dependent on the substituents in the salan ligand environment coordinated to the metal.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.